Joan Josep Cabré

Existe bibliografía que apoya un retraso diagnóstico y terapéutico en mujeres con alto riesgo cardiovascular. El objetivo de este trabajo fue conocer la incidencia de la enfermedad cardiovascular (ECV) y la mortalidad en una cohorte con Síndrome Metabólico (SM), así como analizar posibles diferencias de género y lugar de residencia, respecto a la realización de angioplastias primarias en pacientes con cardiopatía isquémica (CI). Se realizó un estudio de cohorte poblacional apoyándonos en la base de datos SIDIAP (Sistema de Información para la Investigación en Atención Primaria), en Atención Primaria de Cataluña. Seleccionamos personas de ambos sexos, entre 35-75 años, exentos de ECV al inicio (2009), cumpliendo criterios de SM (diagnósticos NCEP-ATPIII [National Cholesterol Education Program-Adult Treatment Panel III]). La variable resultado fue la incidencia a 10 años de ECV y la mortalidad global por toda causa. Registramos variables sociodemográficas (edad, sexo, fenotipo SM, índice socioeconómico MEDEA) y reperfusión coronaria. Se realizó estadística descriptiva, ANOVA y prueba de chi-cuadrado para verificar la diferencia entre variables. 167.673 personas cumplieron criterios de SM (5,2% de la población), de las cuales había 105.969 hombres (63,2%). El 22% de población pertenecía a áreas rurales. Aquellas áreas urbanas más dispares socioeconómicamente (urbana-1 y urbana-5), exhibieron las mayores incidencias de ECV y CI. Registramos 51.129 ECV (30,7%) de los cuales 8.889 fueron infartos agudos de miocardio (IAM; 5,3%) y 24.284 fueron CI (14,5%). Se realizaron 1.758 procedimientos de angioplastia primaria, 1.467 en hombres y 291 en mujeres, representando respectivamente un 4,4% y un 0,9% (p<0.005). La incidencia de IAM y CI en sujetos con SM es alta en Cataluña. Existe diferencia estadísticamente significativa en las angioplastias realizadas, según sexo y lugar de residencia. Probablemente una implicación práctica sería detectar a tiempo la CI en mujeres con SM, para que puedan beneficiarse de la terapia revascularizadora igual que los hombres.

Diabetes mellitus (DM) is the leading cause of polyneuropathy in the Western world. Diabetic neuropathy (DNP) is the most common complication of diabetes and is of great clinical significance mainly due to the pain and the possibility of ulceration in the lower limbs. Early detection of neuropathy is essential in the medical management of this complication. Early unmyelinated C-fiber dysfunction is one of the typical findings of diabetic neuropathy and the first clinical manifestation of dysfunction indicating sudomotor eccrine gland impairment. In order to assess newly developed technology for the measurement of dermal electrochemical conductance (DEC), we analyzed the feasibility and effectiveness of DEC (quantitative expression of sudomotor reflex) as a screening test of DNP in primary health care centers. The study included 197 people (with type 2 diabetes, prediabetes and normal tolerance) who underwent all the protocol tests and electromyography (EMG). On comparing DEC with EMG as the gold standard, the area under the receiver operating characteristic (ROC) curve (AUC, area under the curve) was 0.58 in the whole sample, AUC = 0.65 in the diabetes population and AUC = 0.72 in prediabetes, being irrelevant in subjects without glucose disturbances (AUC = 0.47). Conclusions: In usual clinical practice, DEC is feasible, with moderate sensitivity but high specificity. It is also easy to use and interpret and requires little training, thereby making it a good screening test in populations with diabetes and prediabetes. It may also be useful in screening general populations at risk of neuropathy.

OBJECTIVE The long-term impact of intentional weight loss on cardiovascular events remains unknown. We describe 12-month changes in body weight and cardiovascular risk factors in PREvención con DIeta MEDiterránea (PREDIMED)-Plus, a trial designed to evaluate the long-term effectiveness of an intensive weight loss lifestyle intervention on primary cardiovascular prevention. RESEARCH DESIGN AND METHODS Overweight/obese adults with metabolic syndrome aged 55–75 years (n = 626) were randomized to an intensive weight loss lifestyle intervention based on an energy-restricted Mediterranean diet, physical activity promotion, and behavioral support (IG) or a control group (CG). The primary and secondary outcomes were changes in weight and cardiovascular risk markers, respectively. RESULTS Diet and physical activity changes were in the expected direction, with significant improvements in IG versus CG. After 12 months, IG participants lost an average of 3.2 kg vs. 0.7 kg in the CG (P < 0.001), a mean difference of −2.5 kg (95% CI −3.1 to −1.9). Weight loss ≥5% occurred in 33.7% of IG participants compared with 11.9% in the CG (P < 0.001). Compared with the CG, cardiovascular risk factors, including waist circumference, fasting glucose, triglycerides, and HDL cholesterol, significantly improved in IG participants (P < 0.002). Reductions in insulin resistance, HbA_1c, and circulating levels of leptin, interleukin-18, and MCP-1 were greater in IG than CG participants (P < 0.05). IG participants with prediabetes/diabetes significantly improved glycemic control and insulin sensitivity, along with triglycerides and HDL cholesterol levels compared with their CG counterparts. CONCLUSIONS PREDIMED-Plus intensive lifestyle intervention for 12 months was effective in decreasing adiposity and improving cardiovascular risk factors in overweight/obese older adults with metabolic syndrome, as well as in individuals with or at risk for diabetes.

Con el fin de evidenciar la posible relación entre deprivación y morbimortalidad, enmarcada en diferentes lugares de residencia, diseñamos el presente estudio. El objetivo de este trabajo fue analizar la influencia del lugar de residencia sobre la incidencia de eventos cardiovasculares (ECV) y de mortalidad general por cualquier causa, en una cohorte con síndrome metabólico. Estudio prospectivo para determinar la incidencia de ECV según el lugar de residencia (rural, urbano) en individuos con distintas combinaciones de rasgos clínicos de Síndrome Metabólico (SM). El emplazamiento del mismo fue la Atención Primaria de Cataluña (España). Los sujetos de estudio fueron personas de entre 35-75 años de edad, que cumplían los criterios de SM, sin ECV al inicio del seguimiento (2009). La población se estratificó según el índice MEDEA en rural, y dentro de áreas urbanas en 5 subcategorías (urbano1 - urbano5), según su nivel de deprivación. Se realizó estadística descriptiva, análisis de la varianza y curvas de supervivencia (Kaplan-Meier, método de Cox) para contrastar los diferentes grupos categóricos. Se analizaron 401.743 sujetos con SM (17,2% de la población catalana); 20,1% residían en áreas rurales. Su edad media osciló entre 60,5 + 9,6 años en área urbana 1 (la más favorecida) y 59,6 + 10,4 años en área urbana 5 (la más precaria). A los 5 años de seguimiento, la incidencia global de ECV fue del 5,5%, siendo ligeramente menor en ámbito rural (5%) que en los urbanos (entre 5,5-5,8%). En cambio, la mortalidad fue superior en el ámbito rural (859 casos/100000 habitantes-año) - que en el resto de áreas (mínimo valor en urbano-3 (736 casos/100000 habitantes-año)). El lugar de residencia constituye un marcador de riesgo, que se asocia a la incidencia de ECV pero sobre todo, a una mayor mortalidad por todas las causas, en pacientes con SM. Sin duda y dejando de lado los posibles factores de confusión, en las áreas socioeconómicamente más desfavorecidas, la mortalidad está aumentada.

In order to clarify the relation between deprivation and morbillity and mortality, in function of different residence places, we design this study. Main objective is to analyze the influence of place of residence on the incidence of cardiovascular events (CVD) and general mortality from any cause, in a cohort with metabolic syndrome. Prospective study to determine the incidence of CVD according to the place of residence (rural, urban) in individuals with different combinations of clinical features of Metabolic Syndrome (MS). Setting: Primary Care, Catalonia (Spain). Subjects: between 35-75 years of age fulfilling SM criteria, without CVD at the beginning of follow-up (2009). The population was stratified according to the MEDEA index in rural, and within urban areas in 5 subcategories (urban1 - urban5), according to their level of deprivation. We performed descriptive statistics, variance analysis and survival curves (Kaplan-Meier and Cox methods) in order to contrast data from different categories. We analyzed 401,743 subjects with MS (17.2% of the Catalan population); 20.1% resided in rural areas. Their average age ranged between 60.5 + 9.6 years in urban area 1 (most favored) and 59.6 + 10.4 years in urban area 5 (the most precarious). After 5 years of follow-up, the global incidence of CVD was 5.5%, being slightly lower in rural areas (5%) than in urban areas (between 5.5% -5.8%). On the other hand, mortality was higher in the rural area (859 deaths/100000 inhabitants-year) - than in the rest of the areas (minimum value in urban-3 (736 deaths/100000 inhabitants-year)). The place of residence is a risk marker, which is associated with the incidence of CVD but above all, with higher mortality from all causes in patients with MS. Undoubtedly and leaving aside the possible confounding factors, in the socioeconomically most disadvantaged areas, mortality is increased.

Diabetes mellitus is the leading cause of polyneuropathy in the Western world. Diabetic neuropathy is a frequent complication of diabetes and may have great clinical transcendence due to pain and possible ulceration of the lower extremities. It is also a relevant cause of morbidity and mortality in patients with diabetes. Although the cause of polyneuropathy in patients with diabetes is only partially known, it has been associated with chronic hyperglycemia suggesting the possible etiopathogenic implication of advanced glycosylation end products. The strategy of choice in the medical management of diabetic neuropathy is early detection since glycaemic control and the use of certain drugs may prevent or slow the development of this disease. Diabetic neuropathy most often presents with a dysfunction of unmyelinated C-fibers, manifested as an alteration of the sweat reflex of the eccrine glands. This dysfunction can now be demonstrated using a newly developed technology which measures dermal electrochemical conductivity. This noninvasive test is easy and cost-effective. The aim of the present study is to evaluate the feasibility and effectiveness of dermal electrochemical conductance measurement (quantitative expression of the sudomotor reflex) as a screening test for the diagnosis of diabetic neuropathy in patients in primary care.